BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tian C, Li N, Bai Y, Xiao H, Li S, Ge QG, Shen N, Ma QB. Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension. World J Clin Cases 2021; 9(1): 47-60 [PMID: 33511171 DOI: 10.12998/wjcc.v9.i1.47]
URL: https://www.wjgnet.com/2307-8960/full/v9/i1/47.htm
Number Citing Articles
1
Ye Liu, Ran Lu, Junhong Wang, Qin Cheng, Ruitao Zhang, Shuisheng Zhang, Yunyi Le, Haining Wang, Wenhua Xiao, Hongwei Gao, Lin Zeng, Tianpei Hong. Diabetes, even newly defined by HbA1c testing, is associated with an increased risk of in-hospital death in adults with COVID-19BMC Endocrine Disorders 2021; 21(1) doi: 10.1186/s12902-021-00717-6
2
Farnoosh Nozari, Nasrin Hamidizadeh, Salvatore Corrao. The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-ReviewInternational Journal of Hypertension 2022; 2022: 1 doi: 10.1155/2022/5937802
3
Safaet Alam, Taslima Binte Kamal, Md. Moklesur Rahman Sarker, Jin-Rong Zhou, S. M. Abdur Rahman, Isa Naina Mohamed. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.659577